Longboard Pharmaceuticals Stock (NASDAQ:LBPH)
Previous Close
$59.69
52W Range
$3.60 - $59.95
50D Avg
$41.65
200D Avg
$28.51
Market Cap
$2.32B
Avg Vol (3M)
$1.63M
Beta
1.24
Div Yield
-
LBPH Company Profile
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
LBPH Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| NUVB | Nuvation Bio Inc. |
| DBTX | Decibel Therapeutics, Inc. |
| NXTC | NextCure, Inc. |
| IKNA | Ikena Oncology, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| SNSE | Sensei Biotherapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| GRPH | LENZ Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| CELC | Celcuity Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |
| TIL | Instil Bio, Inc. |